Distinct responses of COL17A1 nonsense variants to readthrough drugs and NOG as a novel enhancer in junctional epidermolysis bullosa.

Variable responses to readthrough drugs in COL17A1 nonsense variants suggest personalized therapy for junctional epidermolysis bullosa.

• Why it matters: Nonsense mutations in COL17A1 cause skin fragility and chronic wounds in JEB, with about 20% of cases involving premature termination codons that reduce functional protein. Addressing these mutations is crucial for developing effective treatments, yet responses to readthrough therapies vary among different variants.
• What they did: Researchers tested a panel of translational readthrough-inducing drugs (TRIDs) on keratinocytes from JEB-C17 patients with distinct nonsense mutations and examined NOG’s role in enhancing readthrough by inhibiting nonsense-mediated decay. They also evaluated NOG combined with TRIDs or a TRID-based cocktail.
• The result: Findings indicate mutation-dependent TRID responses, supporting the need for personalized approaches, and suggest NOG as a potential enhancer of readthrough therapy, advancing preclinical strategies for JEB-C17.